

## PACKAGE LEAFLET: INFORMATION FOR THE USER

### MIRCERA

**50 micrograms/ml solution for injection**  
**100 micrograms/ml solution for injection**  
**200 micrograms/ml solution for injection**  
**300 micrograms/ml solution for injection**  
**400 micrograms/ml solution for injection**  
**600 micrograms/ml solution for injection**  
**1000 micrograms/ml solution for injection**

methoxy polyethylene glycol-epoetin beta

#### **Read all of this leaflet carefully before you start using this medicine.**

- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor or pharmacist.
- This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours.
- If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.

#### **In this leaflet:**

1. What MIRCERA is and what it is used for
2. Before you use MIRCERA
3. How to use MIRCERA
4. Possible side effects
5. How to store MIRCERA
6. Further information

### **1. WHAT MIRCERA IS AND WHAT IT IS USED FOR**

This medicine is prescribed to you because you have anaemia. This means that you have too few red blood cells and your haemoglobin level is too low (your body's tissues might not receive enough oxygen). The symptoms may be fatigue, weakness and shortness of breath.

MIRCERA is a medicine produced by gene-technology. The active ingredient is methoxy polyethylene glycol-epoetin beta. Like the natural hormone erythropoietin, MIRCERA increases the number of red blood cells and haemoglobin level in your blood. Compared to other similar medicines called erythropoiesis stimulating agent (or ESA), MIRCERA can stay in your body longer, therefore fewer injections are required for your treatment.

MIRCERA is used to treat the anaemia caused by your chronic kidney disease. It has not been shown that MIRCERA can be used to treat anaemia caused by other diseases.

### **2. BEFORE YOU USE MIRCERA**

#### **Do not use MIRCERA**

- if you are allergic (hypersensitive) to methoxy polyethylene glycol-epoetin beta or to any of the other ingredients of MIRCERA (see section 6)
- if you have high blood pressure that cannot be controlled

#### **Take special care with MIRCERA**

*Before treatment with MIRCERA*

- A condition called Pure Red Cell Aplasia (stopped or reduced production of red blood cells) due to anti-erythropoietin antibodies was observed in some patients treated with ESAs. If your doctor suspects or confirms that you have these antibodies in your blood you must not be treated with MIRCERA.
- If you are a cancer patient be aware that ESAs and MIRCERA may act as growth factors. Please discuss this with your doctor.
- It is not known if MIRCERA has a different effect in patients with hemoglobinopathies (disorders associated with abnormal haemoglobin), severe liver disease, past or present bleeding, seizures or have a high blood platelet count. If you have any of these conditions your doctor will discuss it with you and must treat you with caution.
- Healthy people should not use MIRCERA. Using it can lead to too high haemoglobin levels and cause problems with the heart or blood vessels that may be life-threatening.

#### *During treatment with MIRCERA*

- Your doctor will check the amount of iron in your blood before and during MIRCERA treatment. If the amount is too low your doctor may give you an additional iron therapy.
- Your doctor will check your blood pressure before and during your MIRCERA treatment. If your blood pressure is high and cannot be controlled either by medicine or a special diet, your doctor will interrupt your MIRCERA treatment or reduce the dose.
- Contact your doctor if you feel tired, weak or have shortness of breath as this could mean that your MIRCERA treatment is not effective. Your doctor will check that you do not have other causes of anaemia and may perform blood tests or examine your bone marrow. If you have developed Pure Red Cell Aplasia your MIRCERA treatment will be discontinued. You will not receive another ESA and your doctor will treat you for this condition.

#### *Children and adolescents*

Treatment with MIRCERA is not recommended in children and adolescents as it has not been studied in these patients.

#### *Important information about some of the ingredients of MIRCERA*

This medicine contains less than 1 mmol sodium (23 mg) per ml, i.e. essentially 'sodium-free'.

#### **Using other medicines**

Please tell your doctor or pharmacist if you are using, or have recently used, any other medicines, including medicines obtained without a prescription.

No interaction studies have been performed. There is no evidence that MIRCERA interacts with other medicines.

#### **Using MIRCERA with food and drink**

Food and drink do not affect MIRCERA.

#### **Pregnancy and breast-feeding**

Ask your doctor or pharmacist for advice before taking any medicine.

MIRCERA has not been studied in pregnant or breast-feeding women.

Tell your doctor if you are pregnant, think you are pregnant or intend to become pregnant. Your doctor will consider what is the best treatment for you during pregnancy.

Tell your doctor if you are breast-feeding or intend to breast-feed. Your doctor will advise if you should stop or continue breast-feeding and stop or continue your treatment.

#### **Driving and using machines**

MIRCERA does not affect your ability to drive and use machines.

### **3. HOW TO USE MIRCERA**

Always use MIRCERA exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure.

Treatment with MIRCERA must be started under the supervision of a healthcare professional. Further injections can be given by a healthcare professional or, after you have been trained, you can inject MIRCERA yourself (see instructions at the end of this leaflet.)

MIRCERA can be injected under the skin in the abdomen, arm or thigh; or into a vein. Your doctor will decide which is best for you.

Your doctor will carry out regular blood tests to monitor how your anaemia is responding to treatment by measuring your haemoglobin level.

- **If you are not currently treated with an ESA**

The recommended starting dose of MIRCERA is 0.6 micrograms for every kilogram of your body weight. The dose is to be administered once every 2 weeks as a single injection.

Your doctor may increase or decrease your dose or temporarily stop your treatment to adjust your haemoglobin level, as appropriate for you. Dose changes will not be made more often than once a month.

Once your anaemia is corrected your doctor may change your dosing to once a month administration.

- **If you are currently being treated with an ESA**

Your doctor may replace your current medicine with MIRCERA. Your doctor will decide to treat you with MIRCERA administered as a single injection once a month. Your doctor will calculate your MIRCERA starting dose based on the last dose of your previous medicine. The first MIRCERA dose will be given on the planned injection day of your previous medicine.

Your doctor may increase or decrease your dose or temporarily stop your treatment to adjust your haemoglobin to an appropriate level for you. Dose changes will not be made more often than once a month.

**If you use more MIRCERA than you should**

Please contact your doctor or pharmacist if you used too large a dose of MIRCERA as it may be necessary to perform some blood tests and interrupt your treatment.

**If you forget to use MIRCERA**

If you miss a dose of MIRCERA administer the missed dose as soon as you remember and talk to your doctor about when to use the next doses.

**If you stop using MIRCERA**

Treatment with MIRCERA is normally long-term. It can, however, be stopped on the advice of your doctor at any time.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

#### **4. POSSIBLE SIDE EFFECTS**

Like all medicines, MIRCERA can cause side effects, although not everybody gets them.

A common side effect (occurring in less than 1 out of 10 patients) is high blood pressure.

Uncommon side effects (occurring in less than 1 out of 100 patients) are:

- headache
- vascular access thrombosis (blood clots in your dialysis access).

Rare side effects (less than 1 in 1000 patients) are:

- hypertensive encephalopathy (very high blood pressure that can result in headache, especially sudden, stabbing, migraine-like headache, confusion, speech disturbances, fits or convulsions). If you have these symptoms please contact your doctor immediately to receive treatment.
- maculo-papular rash (red skin reaction that can include pimples or spots)
- hot flush
- hypersensitivity (severe allergic reaction that can cause unusual wheezing or difficulty in breathing; swollen tongue, face or throat, or swelling around the injection site, or make you feel light-headed, faint or cause you to collapse). If you have these symptoms please contact your doctor immediately to receive treatment.

During clinical studies patients had a slight decrease in their platelet blood counts. Some patients had platelet counts below the normal range.

If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.

## **5. HOW TO STORE MIRCERA**

Keep out of the reach and sight of children.

Do not use MIRCERA after the expiry date which is stated on the outer carton and vial label after 'EXP'. The expiry date refers to the last day of that month.

Store in a refrigerator (2 °C – 8 °C). Do not freeze.

Keep the vial in the outer carton in order to protect from light.

You may remove MIRCERA from the refrigerator and store it at room temperature (not above 25 °C) for a period of one month and on one occasion only. Once you have removed your medicine from the refrigerator you must use it within this period of one month.

Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines that are no longer required. These measures will help to protect the environment.

## **6. FURTHER INFORMATION**

### **What MIRCERA contains**

- The active substance is methoxy polyethylene glycol-epoetin beta. 1 ml (one vial) contains 50, 100, 200, 300, 400, 600, 1000 micrograms methoxy polyethylene glycol-epoetin beta.
- The other ingredients are sodium dihydrogen phosphate monohydrate, sodium sulphate, mannitol (E421), methionine, poloxamer 188 and water for injections.

### **What MIRCERA looks like and contents of the pack**

MIRCERA is a solution for injection in vial.

The solution is clear, colourless to slightly yellowish and free of visible particles.

MIRCERA comes in glass vials with grey laminated rubber stopper and flip-off cap made in aluminium and plastic. Each vial contains 1ml of solution. One pack contains 1 vial.

### **Marketing Authorisation Holder**

Roche Registration Limited  
6 Falcon Way  
Shire Park  
Welwyn Garden City  
AL7 1TW

United Kingdom

**Manufacturer**

Roche Pharma AG  
Emil-Barell-Str. 1  
D-79639 Grenzach-Wyhlen  
Germany

For any information about this medicinal product, please contact the local representative of the Marketing Authorisation Holder:

**België/Belgique/Belgien**

N.V. Roche S.A.  
Tél/Tel: +32 (0) 2 525 82 11

**Luxembourg/Luxemburg**

(Voir/siehe Belgique/Belgien)

**България**

Рош България ЕООД  
Тел: +359 2 818 44 44

**Magyarország**

Roche (Magyarország) Kft.  
Tel: +36 - 23 446 800

**Česká republika**

Roche s. r. o.  
Tel: +420 - 2 20382111

**Malta**

(See United Kingdom)

**Danmark**

Roche a/s  
Tlf: +45 - 36 39 99 99

**Nederland**

Roche Nederland B.V.  
Tel: +31 (0) 348 438050

**Deutschland**

Roche Pharma AG  
Tel: +49 (0) 7624 140

**Norge**

Roche Norge AS  
Tlf: +47 - 22 78 90 00

**Eesti**

Roche Eesti OÜ  
Tel: + 372 - 6 112 401

**Österreich**

Roche Austria GmbH  
Tel: +43 (0) 1 27739

**Ελλάδα**

Roche (Hellas) A.E.  
Τηλ: +30 210 61 66 100

**Polska**

Roche Polska Sp.z o.o.  
Tel: +48 - 22 345 18 88

**España**

Roche Farma S.A.  
Tel: +34 - 91 324 81 00

**Portugal**

Roche Farmacêutica Química, Lda  
Tel: +351 - 21 425 70 00

**France**

Roche  
Tél: +33 (0) 1 46 40 50 00

**România**

Roche România S.R.L.  
Tel: +40 21 206 47 01

**Ireland**

Roche Products (Ireland) Ltd.  
Tel: +353 (0) 1 469 0700

**Slovenija**

Roche farmacevtska družba d.o.o.  
Tel: +386 - 1 360 26 00

**Ísland**

Roche a/s  
c/o Icepharma hf  
Sími: +354 540 8000

**Slovenská republika**

Roche Slovensko, s.r.o.  
Tel: +421 - 2 52638201

**Italia**

Roche S.p.A.  
Tel: +39 - 039 2471

**Κύπρος**

Γ.Α.Σταμάτης & Σια Λτδ.  
Τηλ: +357 - 22 76 62 76

**Latvija**

Roche Latvija SIA  
Tel: +371 - 7 039831

**Lietuva**

UAB "Roche Lietuva"  
Tel: +370 5 2546799

**Suomi/Finland**

Roche Oy  
Puh/Tel: +358 (0) 9 525 331

**Sverige**

Roche AB  
Tel: +46 (0) 8 726 1200

**United Kingdom**

Roche Products Ltd.  
Tel: +44 (0) 1707 366000

**This leaflet was last approved in {MM/YYYY}.**

Detailed information on this medicine is available on the European Medicines Agency (EMA) web site: <http://www.emea.europa.eu/>.

---

**HOW TO SELF INJECT MIRCERA**

Always take MIRCERA exactly as your doctor has told you. Check with your doctor or nurse if you are unsure.

MIRCERA can be self-injected by yourself either under the skin or if you are on haemodialysis, through the haemodialysis line according to your doctor's advice.

The vial does not contain any preservative and is to be used for one single injection only. More than one dose must not be administered per vial.

Do not mix the solution with other injectable medicines. Store the vial in the outer carton box.

**Safety tips**

- Remove the vial of MIRCERA from the refrigerator and allow it to reach room temperature in its outer carton box. This should take about 30 minutes after the package has been removed from the fridge.
- Make sure that the vial has not been removed from the fridge for more than a single period or for longer than 1 month.
- Do not use a vial that has been frozen and do not expose it to temperatures above 25 °C.
- Do not use a vial after the expiry date stated on the label.
- Only use the vial if the solution is clear, colourless (slightly yellow in colour is acceptable) and is free of visible particles.
- Do not shake the vial.
- When handling syringes, do not touch the needles.
- Keep the syringes in their wrappers until you are ready to prepare your dose.

**Getting started**

Assemble all of the supplies you will need for an injection on a clean surface:

Included in the pack:

- One vial of MIRCERA

Not included in the pack:

- A syringe


- One long needle to withdraw MIRCERA from the vial
- One short needle for injection
- Cleansing alcohol swabs
- Sterile gauze
- Container for the waste material

The following instructions explain how to use MIRCERA vials to inject yourself. Please read the instructions carefully and follow them step by step.


Wash your hands thoroughly before you start.

### Preparing the dose of MIRCERA


- Remove the protective cap from the vial (1).
- Clean the rubber top of the vial with a cleansing alcohol swab.




- Remove the syringe from the wrapping. Do not touch the tip of the syringe.
- Take the needle guard containing the long needle and place it firmly on to the tip of the syringe (2).



- Remove the needle guard without touching the needle and keep the syringe with the needle in your hand.
- Insert the needle through the rubber stopper into the vial (3).




- Hold the vial firmly in one hand and the syringe in the other and turn both upside down (4).



4

- Keeping the vial upside down, slowly pull back on the plunger to fill the syringe with the solution to the line that matches the dose your doctor prescribed.
- Keeping the vial upside down and the needle in the vial, check for air bubbles in the syringe. To remove air bubbles, gently tap the syringe with your fingers until the air bubbles rise to the top of the syringe. Then slowly push the plunger up to push the solution and the air bubbles out of the syringe.
- Keep the tip of the needle in the liquid and once again pull the plunger back to the line on the syringe that matches your dose.
- Remove the syringe from the long needle while keeping the needle in the vial. Avoid touching the tip of the syringe.
- Take the needle guard containing the short injection needle and place it firmly on to the tip of the syringe (5).




5

### Injecting the solution

If your doctor has advised you to inject MIRCERA through the haemodialysis line or into a vein, please administer your dose as shown by your health care professional.

If you are advised to inject MIRCERA under your skin please administer your dose as described below.


- Select the injection site in the abdomen, thigh or arm (except your navel or waistline) (6).



6

- Clean the skin, where the injection is to be made with a cleansing alcohol swab.
- Wait for the area to dry.
- Remove the needle guard.

- With one hand, pinch a fold of loose skin. Insert the short injection needle into the pinched skin, holding the syringe like a pencil, use a quick “dart like” motion to insert the injection needle either straight up and down (90 degrees angle) or at a slight angle (45 degrees angle) into the skin, as shown by your health care professional (7).



- Inject the solution by gently pushing the plunger all the way down.
- Pull the injection needle straight out of the skin.
- Press on the injection site with a small bandage or sterile gauze for several seconds.
- Do not massage the injection site. Any bleeding may be covered with an adhesive bandage.

### **Disposal**

The syringe, needles and all injection materials are intended for single use and must be discarded after the injection. Dispose off the syringe and needles safely in a closed container.

## PACKAGE LEAFLET: INFORMATION FOR THE USER

### MIRCERA

**50 micrograms/0.3 ml solution for injection in pre-filled syringe**  
**75 micrograms/0.3 ml solution for injection in pre-filled syringe**  
**100 micrograms/0.3 ml solution for injection in pre-filled syringe**  
**150 micrograms/0.3 ml solution for injection in pre-filled syringe**  
**200 micrograms/0.3 ml solution for injection in pre-filled syringe**  
**250 micrograms/0.3 ml solution for injection in pre-filled syringe**  
**400 micrograms/0.6 ml solution for injection in pre-filled syringe**  
**600 micrograms/0.6 ml solution for injection in pre-filled syringe**  
**800 micrograms/0.6 ml solution for injection in pre-filled syringe**

methoxy polyethylene glycol-epoetin beta

#### **Read all of this leaflet carefully before you start using this medicine.**

- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor or pharmacist.
- This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours.
- If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.

#### **In this leaflet:**

1. What MIRCERA is and what it is used for
2. Before you use MIRCERA
3. How to use MIRCERA
4. Possible side effects
5. How to store MIRCERA
6. Further information

### **1. WHAT MIRCERA IS AND WHAT IT IS USED FOR**

This medicine is prescribed to you because you have anaemia. This means that you have too few red blood cells and your haemoglobin level is too low (your body's tissues might not receive enough oxygen). The symptoms may be fatigue, weakness and shortness of breath.

MIRCERA is a medicine produced by gene-technology. The active ingredient is methoxy polyethylene glycol-epoetin beta. Like the natural hormone erythropoietin, MIRCERA increases the number of red blood cells and haemoglobin level in your blood. Compared to other similar medicines called erythropoiesis stimulating agent (or ESA). MIRCERA can stay in your body longer, therefore fewer injections are required for your treatment.

MIRCERA is used to treat the anaemia caused by your chronic kidney disease. It has not been shown that MIRCERA can be used to treat anaemia caused by other diseases.

### **2. BEFORE YOU USE MIRCERA**

#### **Do not use MIRCERA**

- if you are allergic (hypersensitive) to methoxy polyethylene glycol-epoetin beta or to any of the other ingredients of MIRCERA (see section 6)
- if you have high blood pressure that cannot be controlled

#### **Take special care with MIRCERA**

#### *Before treatment with MIRCERA*

- A condition called Pure Red Cell Aplasia (stopped or reduced production of red blood cells) due to anti-erythropoietin antibodies was observed in some patients treated with ESAs. If your doctor suspects or confirms that you have these antibodies in your blood you must not be treated with MIRCERA.
- If you are a cancer patient be aware that ESAs and MIRCERA may act as growth factors. Please discuss this with your doctor.
- It is not known if MIRCERA has a different effect in patients with hemoglobinopathies (disorders associated with abnormal haemoglobin), severe liver disease, past or present bleeding, seizures or have a high blood platelet count. If you have any of these conditions your doctor will discuss it with you and must treat you with caution.
- Healthy people should not use MIRCERA. Using it can lead to too high haemoglobin levels and cause problems with the heart or blood vessels that may be life-threatening.

#### *During treatment with MIRCERA*

- Your doctor will check the amount of iron in your blood before and during MIRCERA treatment. If the amount is too low your doctor may give you an additional iron therapy.
- Your doctor will check your blood pressure before and during your MIRCERA treatment. If your blood pressure is high and cannot be controlled either by medicine or a special diet, your doctor will interrupt your MIRCERA treatment or reduce the dose.
- Contact your doctor if you feel tired, weak or have shortness of breath as this could mean that your MIRCERA treatment is not effective. Your doctor will check that you do not have other causes of anaemia and may perform blood tests or examine your bone marrow. If you have developed Pure Red Cell Aplasia your MIRCERA treatment will be discontinued. You will not receive another ESA and your doctor will treat you for this condition.

#### *Children and adolescents*

Treatment with MIRCERA is not recommended in children and adolescents as it has not been studied in these patients.

#### *Important information about some of the ingredients of MIRCERA*

This medicine contains less than 1 mmol sodium (23 mg) per ml, i.e. essentially 'sodium-free'.

#### **Using other medicines**

Please tell your doctor or pharmacist if you are using, or have recently used, any other medicines, including medicines obtained without a prescription.

No interaction studies have been performed. There is no evidence that MIRCERA interacts with other medicines.

#### **Using MIRCERA with food and drink**

Food and drink do not affect MIRCERA.

#### **Pregnancy and breast-feeding**

Ask your doctor or pharmacist for advice before taking any medicine.

MIRCERA has not been studied in pregnant or breast-feeding women.

Tell your doctor if you are pregnant, think you are pregnant or intend to become pregnant. Your doctor will consider what is the best treatment for you during pregnancy.

Tell your doctor if you are breast-feeding or intend to breast-feed. Your doctor will advise if you should stop or continue breast-feeding and stop or continue your treatment.

#### **Driving and using machines**

MIRCERA does not affect your ability to drive and use machines.

### **3. HOW TO USE MIRCERA**

Always use MIRCERA exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure.

Treatment with MIRCERA must be started under the supervision of a healthcare professional. Further injections can be given by a healthcare professional or, after you have been trained, you can inject MIRCERA yourself (see instructions at the end of this leaflet.)

MIRCERA can be injected under the skin in the abdomen, arm or thigh; or into a vein. Your doctor will decide which is best for you.

Your doctor will carry out regular blood tests to monitor how your anaemia is responding to treatment by measuring your haemoglobin level.

- **If you are not currently treated with an ESA**

The recommended starting dose of MIRCERA is 0.6 micrograms for every kilogram of your body weight. The dose is to be administered once every 2 weeks as a single injection.

Your doctor may increase or decrease your dose or temporarily stop your treatment to adjust your haemoglobin level, as appropriate for you. Dose changes will not be made more often than once a month.

Once your anaemia is corrected your doctor may change your dosing to once a month administration.

- **If you are currently being treated with an ESA**

Your doctor may replace your current medicine with MIRCERA. Your doctor will decide to treat you with MIRCERA administered as a single injection once a month. Your doctor will calculate your MIRCERA starting dose based on the last dose of your previous medicine. The first MIRCERA dose will be given on the planned injection day of your previous medicine.

Your doctor may increase or decrease your dose or temporarily stop your treatment to adjust your haemoglobin to an appropriate level for you. Dose changes will not be made more often than once a month.

**If you use more MIRCERA than you should**

Please contact your doctor or pharmacist if you used too large a dose of MIRCERA as it may be necessary to perform some blood tests and interrupt your treatment.

**If you forget to use MIRCERA**

If you miss a dose of MIRCERA administer the missed dose as soon as you remember and talk to your doctor about when to use the next doses.

**If you stop using MIRCERA**

Treatment with MIRCERA is normally long-term. It can, however, be stopped on the advice of your doctor at any time.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

#### **4. POSSIBLE SIDE EFFECTS**

Like all medicines, MIRCERA can cause side effects, although not everybody gets them.

A common side effect (occurring in less than 1 out of 10 patients) is high blood pressure.

Uncommon side effects (occurring in less than 1 out of 100 patients) are:

- headache

- vascular access thrombosis (blood clots in your dialysis access).

Rare side effects (less than 1 in 1000 patients) are:

- hypertensive encephalopathy (very high blood pressure that can result in headache, especially sudden, stabbing, migraine-like headache, confusion, speech disturbances, fits or convulsions). If you have these symptoms please contact your doctor immediately to receive treatment.
- maculo-papular rash (red skin reaction that can include pimples or spots)
- hot flush
- hypersensitivity (severe allergic reaction that can cause unusual wheezing or difficulty in breathing; swollen tongue, face or throat, or swelling around the injection site, or make you feel light-headed, faint or cause you to collapse). If you have these symptoms please contact your doctor immediately to receive treatment.

During clinical studies patients had a slight decrease in their platelet blood counts. Some patients had platelet counts below the normal range.

If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.

## **5. HOW TO STORE MIRCERA**

Keep out of the reach and sight of children.

Do not use MIRCERA after the expiry date which is stated on the outer carton and pre-filled syringe label after 'EXP'. The expiry date refers to the last day of that month.

Store in a refrigerator (2 °C – 8 °C). Do not freeze.

Keep the pre-filled syringe in the outer carton in order to protect from light.

You may remove MIRCERA from the refrigerator and store it at room temperature (not above 25 °C) for a period of one month and on one occasion only. Once you have removed your medicine from the refrigerator you must use it within this period of one month.

Medicines should not be disposed of via wastewater or household waste.

Ask your pharmacist how to dispose of medicines that are no longer required. These measures will help to protect the environment.

## **6. FURTHER INFORMATION**

### **What MIRCERA contains**

- The active substance is methoxy polyethylene glycol-epoetin beta. 0.3 ml or 0.6 ml (one pre-filled syringe) contains 50, 75, 100, 150, 200, 250 micrograms or 400, 600, 800 micrograms.
- The other ingredients are sodium dihydrogen phosphate monohydrate, sodium sulphate, mannitol (E421), methionine, poloxamer 188 and water for injections.

### **What MIRCERA looks like and contents of the pack**

MIRCERA 0.3 ml or 0.6 ml is a solution for injection in pre-filled syringe.

The solution is clear, colourless to slightly yellowish and free of visible particles.

MIRCERA comes in pre-filled syringes with laminated plunger stopper and tip cap with one needle 27G1/2. Each pre-filled syringe contains 0.3 ml or 0.6 ml. One pack contains 1 pre-filled syringe.

### **Marketing Authorisation Holder**

Roche Registration Limited  
6 Falcon Way

Shire Park  
Welwyn Garden City  
AL7 1TW  
United Kingdom

**Manufacturer**

Roche Diagnostics GmbH  
Sandhoferstrasse 116  
D-68305 Mannheim  
Germany

For any information about this medicinal product, please contact the local representative of the Marketing Authorisation Holder:

**België/Belgique/Belgien**

N.V. Roche S.A.  
Tél/Tel: +32 (0) 2 525 82 11

**Luxembourg/Luxemburg**

(Voir/siehe Belgique/Belgien)

**България**

Рош България ЕООД  
Тел: +359 2 818 44 44

**Magyarország**

Roche (Magyarország) Kft.  
Tel: +36 - 23 446 800

**Česká republika**

Roche s. r. o.  
Tel: +420 - 2 20382111

**Malta**

(See United Kingdom)

**Danmark**

Roche a/s  
Tlf: +45 - 36 39 99 99

**Nederland**

Roche Nederland B.V.  
Tel: +31 (0) 348 438050

**Deutschland**

Roche Pharma AG  
Tel: +49 (0) 7624 140

**Norge**

Roche Norge AS  
Tlf: +47 - 22 78 90 00

**Eesti**

Roche Eesti OÜ  
Tel: + 372 - 6 112 401

**Österreich**

Roche Austria GmbH  
Tel: +43 (0) 1 27739

**Ελλάδα**

Roche (Hellas) A.E.  
Τηλ: +30 210 61 66 100

**Polska**

Roche Polska Sp.z o.o.  
Tel: +48 - 22 345 18 88

**España**

Roche Farma S.A.  
Tel: +34 - 91 324 81 00

**Portugal**

Roche Farmacêutica Química, Lda  
Tel: +351 - 21 425 70 00

**France**

Roche  
Tél: +33 (0) 1 46 40 50 00

**România**

Roche România S.R.L.  
Tel: +40 21 206 47 01

**Ireland**

Roche Products (Ireland) Ltd.  
Tel: +353 (0) 1 469 0700

**Slovenija**

Roche farmacevtska družba d.o.o.  
Tel: +386 - 1 360 26 00

**Ísland**

Roche a/s  
c/o Icepharma hf  
Sími: +354 540 8000

**Italia**

Roche S.p.A.  
Tel: +39 - 039 2471

**Κύπρος**

Γ.Α.Σταμάτης & Σια Λτδ.  
Τηλ: +357 - 22 76 62 76

**Latvija**

Roche Latvija SIA  
Tel: +371 - 7 039831

**Lietuva**

UAB "Roche Lietuva"  
Tel: +370 5 2546799

**Slovenská republika**

Roche Slovensko, s.r.o.  
Tel: +421 - 2 52638201

**Suomi/Finland**

Roche Oy  
Puh/Tel: +358 (0) 9 525 331

**Sverige**

Roche AB  
Tel: +46 (0) 8 726 1200

**United Kingdom**

Roche Products Ltd.  
Tel: +44 (0) 1707 366000

**This leaflet was last approved in {MM/YYYY}.**

Detailed information on this medicine is available on the European Medicines Agency (EMA) web site: <http://www.ema.europa.eu/>.

---

**HOW TO SELF INJECT MIRCERA**

Always take MIRCERA exactly as your doctor has told you. Check with your doctor or nurse if you are unsure.

The MIRCERA pre-filled syringe is ready for use and can be self-injected by yourself either under the skin or if you are on haemodialysis, through the haemodialysis line according to your doctor's advice. The pre-filled syringe does not contain any preservative and is to be used for one single injection only. More than one dose must not be administered per pre-filled syringe.

Do not mix the solution with other injectable medicines. Store the pre-filled syringe in the outer carton box.

**Safety tips**

- Remove the pre-filled syringe from the refrigerator and allow it to reach room temperature in its outer carton box. This should take about 30 minutes after the package has been removed from the fridge.
- Make sure that the pre-filled syringe has not been removed from the fridge for more than a single period or for longer than 1 month.
- Do not use a pre-filled syringe that has been frozen and do not expose it to temperatures above 25°C.
- Do not use a pre-filled syringe after the expiry date stated on the label.
- Only use the pre-filled syringe if the solution is clear, colourless (slightly yellow in colour is acceptable) and is free of visible particles.
- Do not shake the pre-filled syringe.
- When handling the syringe, do not touch the needle.

**Getting started**

Assemble all of the supplies you will need for an injection on a clean surface:

Included in the pack:

- A pre-filled syringe of MIRCERA and a separate injection needle

Not included in the pack:


- Cleansing alcohol swabs
- Sterile gauze
- A container for the waste material

The following instructions explain how to use MIRCERA pre-filled syringes to inject yourself. Please read the instructions carefully and follow them step by step.


Wash your hands thoroughly before you start.

### Preparing the MIRCERA pre-filled syringe and the needle for injection


- Take the pre-filled syringe and the needle out of the blister




Picture 1. Break the seal and remove the plastic cap from the back of the needle. Do not remove the needle guard at this time.



Picture 2. Remove the syringe tip cap



Picture 3. Attach the needle to the syringe




Picture 4. Remove the needle guard

### Injecting the solution


If your doctor has advised you to inject MIRCERA through the haemodialysis line or into a vein, please administer your dose as shown by your health care professional.  
If you are advised to inject MIRCERA under your skin please administer your dose as described below.

- To remove air bubbles from the syringe, hold the syringe with the needle pointing up. Tap the syringe gently to bring any bubbles to the top. Push the plunger up slowly to the correct dose, as shown to you by a health care professional.




Picture 5. Select the injection site in the arm, abdomen or thigh (except your navel or waistline)

- Clean the skin where the injection is to be made with a cleansing alcohol swab.
- Wait for the area to dry.
- With one hand, pinch a fold of loose skin. Insert the needle into the pinched skin, holding the syringe like a pencil, use a quick “dart like” motion to insert the needle either straight up and down (90 degrees angle) or at a slight angle (45 degrees angle) into the skin, as shown by your health care professional.



Picture 6. Press plunger while holding the finger rests until the full dose has been given.

### Removing the needle



Picture 7. Only once the full dose has been given, release the plunger fully. The entire needle will be removed automatically from the skin and safely guarded.

- Press the injection site with a small bandage or sterile gauze for several seconds.
- Do not massage the injection site.
- Any bleeding may be covered with an adhesive bandage.

**Disposal**

The syringe is intended for single use and must be thrown away after the injection. Dispose off the syringe in a closed container.